Travere Therapeutics (TVTX) Amortization of Deferred Charges (2016 - 2022)
Travere Therapeutics' Amortization of Deferred Charges history spans 9 years, with the latest figure at $428000.0 for Q4 2022.
- For Q4 2022, Amortization of Deferred Charges fell 85.17% year-over-year to $428000.0; the TTM value through Dec 2022 reached $1.6 million, down 73.28%, while the annual FY2025 figure was $1.6 million, 4.93% down from the prior year.
- Amortization of Deferred Charges reached $428000.0 in Q4 2022 per TVTX's latest filing, roughly flat from $428000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $2.9 million in Q4 2021 to a low of $50000.0 in Q3 2018.
- Average Amortization of Deferred Charges over 5 years is $1.2 million, with a median of $428000.0 recorded in 2022.
- Peak YoY movement for Amortization of Deferred Charges: skyrocketed 348.0% in 2019, then crashed 87.65% in 2022.
- A 5-year view of Amortization of Deferred Charges shows it stood at $2.4 million in 2018, then increased by 3.64% to $2.5 million in 2019, then increased by 7.3% to $2.7 million in 2020, then rose by 7.33% to $2.9 million in 2021, then crashed by 85.17% to $428000.0 in 2022.
- Per Business Quant, the three most recent readings for TVTX's Amortization of Deferred Charges are $428000.0 (Q4 2022), $428000.0 (Q3 2022), and $429000.0 (Q2 2022).